TY - JOUR
T1 - Blood genome expression profiles in infants with congenital cytomegalovirus infection
AU - Ouellette, Christopher P.
AU - Sánchez, Pablo J.
AU - Xu, Zhaohui
AU - Blankenship, Derek
AU - Zeray, Fiker
AU - Ronchi, Andrea
AU - Shimamura, Masako
AU - Chaussabel, Damien
AU - Lee, Lizette
AU - Owen, Kris E.
AU - Shoup, Angela G.
AU - Ramilo, Octavio
AU - Mejias, Asuncion
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Congenital CMV infection (cCMVi) affects 0.5–1% of all live births worldwide, making it the leading cause of sensorineural hearing loss (SNHL) in childhood. The majority of infants with cCMVi have normal hearing at birth, but are at risk of developing late-onset SNHL. Currently, we lack reliable biomarkers to predict the development of SNHL in these infants. Here, we evaluate blood transcriptional profiles in 80 infants with cCMVi (49 symptomatic, 31 asymptomatic), enrolled in the first 3 weeks of life, and followed for 3 years to assess emergence of late-onset SNHL. The biosignatures of symptomatic and asymptomatic cCMVi are indistinguishable, suggesting that immune responses of infants with asymptomatic and symptomatic cCMVi are not different. Random forest analyses of initial samples in infants with cCMVi, irrespective of their clinical classification, identify a 16-gene classifier signature associated with the development of SNHL with 92% accuracy, suggesting its potential value as a biomarker.
AB - Congenital CMV infection (cCMVi) affects 0.5–1% of all live births worldwide, making it the leading cause of sensorineural hearing loss (SNHL) in childhood. The majority of infants with cCMVi have normal hearing at birth, but are at risk of developing late-onset SNHL. Currently, we lack reliable biomarkers to predict the development of SNHL in these infants. Here, we evaluate blood transcriptional profiles in 80 infants with cCMVi (49 symptomatic, 31 asymptomatic), enrolled in the first 3 weeks of life, and followed for 3 years to assess emergence of late-onset SNHL. The biosignatures of symptomatic and asymptomatic cCMVi are indistinguishable, suggesting that immune responses of infants with asymptomatic and symptomatic cCMVi are not different. Random forest analyses of initial samples in infants with cCMVi, irrespective of their clinical classification, identify a 16-gene classifier signature associated with the development of SNHL with 92% accuracy, suggesting its potential value as a biomarker.
UR - http://www.scopus.com/inward/record.url?scp=85088036232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088036232&partnerID=8YFLogxK
U2 - 10.1038/s41467-020-17178-5
DO - 10.1038/s41467-020-17178-5
M3 - Article
C2 - 32669541
AN - SCOPUS:85088036232
SN - 2041-1723
VL - 11
JO - Nature communications
JF - Nature communications
IS - 1
M1 - 3548
ER -